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Functional evaluation of PDGFB-
variants in idiopathic basal ganglia 
calcification, using patient-derived 
ips cells
shin-ichiro sekine1,2, Masayuki Kaneko  1,3, Masaki tanaka4, Yuhei Ninomiya1, 
Hisaka Kurita1, Masatoshi Inden1, Megumi Yamada5, Yuichi Hayashi5, Takashi Inuzuka5, 
Jun Mitsui4, Hiroyuki Ishiura  4, Atsushi Iwata4, Hiroto Fujigasaki6, Hisamitsu tamaki7, 
Ryusei tamaki8, Shinsuke Kito8, Yoshiharu taguchi9, Kortaro tanaka9, Naoki Atsuta10, 
Gen sobue10, Takayuki Kondo2,11,12, Haruhisa Inoue  2,11,12, Shoji tsuji  4 & Isao Hozumi1,5
Causative genes in patients with idiopathic basal ganglia calcification (IBGC) (also called primary familial 
brain calcification (PFBC)) have been reported in the past several years. In this study, we surveyed the 
clinical and neuroimaging data of 70 sporadic patients and 16 families (86 unrelated probands in total) 
in Japan, and studied variants of PDGFB gene in the patients. Variant analyses of PDGFB showed four 
novel pathogenic variants, namely, two splice site variants (c.160 + 2T > A and c.457−1G > T), one 
deletion variant (c.33_34delCT), and one insertion variant (c.342_343insG). Moreover, we developed 
iPS cells (iPSCs) from three patients with PDGFB variants (c.160 + 2T > A, c.457−1G > T, and c.33_34 
delCT) and induced endothelial cells. Enzyme-linked immunoassay analysis showed that the levels of 
PDGF-BB, a homodimer of PDGF-B, in the blood sera of patients with PDGFB variants were significantly 
decreased to 34.0% of that of the control levels. Those in the culture media of the endothelial cells 
derived from iPSCs of patients also significantly decreased to 58.6% of the control levels. As the 
endothelial cells developed from iPSCs of the patients showed a phenotype of the disease, further 
studies using IBGC-specific iPSCs will give us more information on the pathophysiology and the therapy 
of IBGC in the future.
Idiopathic basal ganglia calcification (IBGC), also known as Fahr’s disease1 or recently referred to as primary 
familial brain calcification (PFBC)2, is a rare and intractable disease. It is characterized by abnormal deposits of 
minerals including calcium (Ca) in the basal ganglia and other brain regions, such as the thalamus and cerebel-
lum. Most cases are idiopathic in Japan. Regarding the diagnosis of IBGC, other secondary causes of calcification 
should be excluded1,2. The diverse clinical manifestations of IBGC include parkinsonism, cerebellar symptoms, 
cognitive impairment, psychosis, seizures, and chronic headache2. The following causative genes for familial 
IBGC (FIBGC) have been successively identified: SLC20A2 (IBGC1 [previously called IBGC3 and now referred to 
as IBGC1])3, PDGFRB (IBGC4)4, PDGFB (IBGC5)5, XPR1 (IBGC6)6 as autosomal dominant traits, and MYORG7 
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as an autosomal recessive trait. Myorg mRNA is expressed in astrocytes, and this may provide new insights on the 
mechanism underlying brain calcification6.
Several studies, including our studies, have shown that SLC20A2 variants are the most frequent in patients 
with IBGC in many countries2,8–10. PDGFRB variants encoding platelet-derived growth factor (PDGF) receptor-β 
(PDGFRβ), PDGFB encoding its ligand, and XPR-1 encoding a transporter which exports inorganic phosphorus 
(Pi) out of the cells, have been reported in the past several years. In this study, we conducted a nationwide survey 
for PDGFB variant in Japanese patients with IBGC.
PDGF is a dimeric glycoprotein which is composed of two subunits from the four components: A, B, C, and 
D. PDGFR, the receptor of PDGF, is classified as a receptor tyrosine kinase. PDGF-B is expressed in vascular 
endothelial cells and neurons in the brain5,11. PDGF-BB, a homodimer of PDGF-B, stimulates pericytes which are 
abundant in the brain12.
The specific treatment has not been found yet for patients with IBGC, including those with PDGFB variants. 
Mice models carrying hypomorphic human pdgfb alleles have been developed and showed calcium deposits in 
the brain5. However, the genetic pathophysiological mechanisms and the calcification sites in mice were different 
from those of humans5. We produced iPS cells (iPSCs) from a patient with SLC20A2 variant13. New models of 
IBGC, including iPSCs, should be developed for further investigation, especially for drug treatment. Then, we 
developed iPSCs from patients with PDGFB variants and induced the endothelial cells. They mainly produce 
PDGF-BB which stimulates the pericytes in the brain. The breakdown of the pathway due to the loss of function is 
thought to cause the disruption of pericytes14 and blood brain barrier (BBB)15–18. The decrease in the production 
of PDGF-BB in endothelial cells may be a target for the therapy for patients with PDGFB variants.
We have observed higher levels of Pi in CSF not only in patients with SLC20A2 variants but in other patients 
without variants than those of controls19. The role and presence of Pi is critical in the pathogenesis of IBGC in 
addition to Ca. This shows the disturbance in the intracellular uptake of Pi in patients with IBGC. PDGF-BB 
has been reported to stimulate the activation of a Pi transporter, PiT-1, which is encoded by SLC20A1, and 
increases the intracellular uptake of Pi in the vascular smooth muscle cells20. In this study we evaluated the level 
of PDGF-BB in sera and culture media of endothelial cells derived from iPSCs of humans.
Results
Variant analysis. We sequenced the PDGFB gene in 70 sporadic patients with IBGC and 16 families (86 
unrelated probands in total) in Japan, using the Sanger method sequencing of all coding regions. Four variants s 
were found in PDGFB: two variants at the splice junctions (Case 1: c.160 + 2T > A; Case 2: c.457−1G > T), one 
deletion variant (Case 3: c.33_34delCT), and one insertion variant (Case 4: c.342_343insG) (Table 1, Fig. 1). 
Electropherograms indicated that all variants were heterozygous (Supplementary Fig. 1). None of the variants 
were found in an in-house exome sequencing data set (358 Japanese control participants), dbSNP build 151 
(https://www.ncbi.nlm.nih.gov/projects/SNP), Genome Aggregation Database (gnomAD) version 2.0 (http://
gnomad.broadinstitute.org), Japanese Multi Omics Reference Panel (jMorp) (https://jmorp.megabank.tohoku.
ac.jp), and the Human Gene Mutation Database (HGMD) professional 2018.2 (http://www.hgmd.cf.ac.uk). 
When confined to FIBGC, two of the 16 (12.5%) families showed PDGFB variants. In contrast, two of the 70 
(2.9%) patients with sporadic IBGC carried PDGFB variants.
Case 1 Case 2 Case 3 Case 4
Variant
c.160 + 2T > A c.457−1G > T c.33_34delCT c.342_343insG
p.Cys12Leufs*20 p.Asn115Glnfs*52
Zygosity Hetero Hetero Hetero Hetero
Exon 2 5 1 4
Proband’s information
Age at the detection of calcification, y 57 14 71 53
Age at onset, y 57 10 70 56
Symptoms anxiety depression headache school refusal dizziness dementia avolition
Neurological findings
cognitive impairment (MMSE) 28 NE 23 13
pyramidal sign − − − −
extrapyramidal sign − − + −
cerebellar sign + − − −
Family’s information (except for the proband)
Number of other individuals with calcification 1 2 NE NE
Number of other individuals with confirmed variants 1 2 − −
Number of other symptomatic individuals 1 1 − −
Other symptoms (number) in the family panic disorder (1) MR (1) − −
Table 1. Clinical features of the four individuals (probands) with PDGFB variants. Abbreviations: NE = not 
examined, N/A = not applicable, MMSE = mini-mental state examination, MR = mental retardation.
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Clinical manifestations and variants in the probands and their families Familial cases. Case 1 
(in family 1). The proband (Fig. 2a; II-2) in the family was a 57-year-old man who was experiencing depression, 
anxiety, and mild cognitive impairment for 3 years. His neurologic examination findings revealed mild cerebellar 
ataxia (Table 1). Computed tomography (CT) images revealed marked calcification in the bilateral globus palli-
dus, caudate nuclei, pulvinar thalami, and dentate nuclei (Fig. 2b). His deceased father (Fig. 2a; I-1) had demen-
tia. Moreover, CT images of his father showed similar findings to those of the proband (Fig. 2c). The son of the 
proband (Fig. 2a; III-1) had been treated for panic disorder since his teen years. He had the same variant as that of 
the proband. However, we have not confirmed brain calcification on CT images of III-1.
Case 2 (in family 2). The proband (Fig. 3a; II-2) was a 16-year-old woman. She presented with headaches 
and had been refusing to attend school since 10 years old. Her neurological examination findings were normal 
(Table 1). CT images revealed spotty calcification in the bilateral globus pallidus and caudate nuclei and mild cal-
cification in the thalamus, subcortical white matter, and dentate nuclei (Fig. 3b). Her mother (Fig. 3a; I-2) had the 
same variant, and she also presented with headaches and prominent calcification in the bilateral globus pallidus, 
caudate nuclei, thalamus, dentate nuclei, and subcortical white matter (Fig. 3c). On the basis of these results, the 
Figure 1. PDGFB variants and PDGF-B protein. (Upper) Schematic diagrams of PDGFB with variants. Four 
PDGF variants (one insertion variant in exon 4 [c.342_343insG], one deletion variant in exon 1 [c.33_34delCT], 
and two splice site variants in exon 2 [c.160 + 2T > A] and exon 5 [c.457−1G > T]) were found in the PDGFB 
gene. (Lower) Schematic structure of the PDGF-B protein with variants. aa = amino acid.
Figure 2. FIBGC (Case 1 in family 1). (a) Pedigree of family 1. The arrow indicates the index subject. Filled 
symbols represent patients with brain calcification. Participants’ ages are shown under the symbols in the 
pedigree of those whose data were available. The symbols + and − indicate variant carriers and noncarriers, 
respectively, as determined via genetic analysis. The striped symbol represents a variant carrier, although the CT 
image was not available for the study. (b) CT images of the proband (II-2). (c) CT images of the proband’s father 
with variant (I-1). Subdural hematoma was also identified on CT scan.
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calcification was believed to progress with age. Although her third brother (Fig. 3a; II-5) was asymptomatic, he 
showed mild calcification in the globus pallidus on CT images obtained when he encountered a traffic accident 
(Fig. 3d). Considering his age, this calcification was pathologic (total calcification score = 6)21. The calcification 
in other regions of the brain, including the dentate nuclei of the cerebellum, could not be detected. DNA analysis 
revealed the same variant (Fig. 3a; II-5). Her eldest brother did not present with the variant. Thus, no calcifica-
tion was observed on CT images (data not shown) (Fig. 3a; II-1). Her younger sister was in a nursing institution 
because of mental retardation, and a detailed clinical information about her sister was not available (Fig. 3a; II-4).
Sporadic cases. Case 3. The patient was a 71-year-old man who often presented with dizziness since 70 
years old. He had mild cognitive impairment (mini-mental state examination [MMSE] score: 23) and mild brad-
ykinesia based on his neurological examination (Table 1). Brain CT images showed calcified areas in the bilateral 
globus pallidus, caudate nuclei, pulvinar thalami, dentate nuclei, and subcortical and periventricular regions 
(Fig. 4a).
Case 4. The patient was a 60-year-old woman who had memory impairment accompanied with avolition since 
50 years old. At age of 53, brain calcification was detected on CT images. She developed dementia at age 56 and 
underwent a medical examination at age 60. Her MMSE score was 13. She presented with impaired postural 
reflexes and signs of frontal lobe impairment, and she did not have any other neurological problems except for 
postural instability (Table 1). Brain CT images revealed calcification in the bilateral globus pallidus, caudate 
nuclei, pulvinar thalami, dentate nuclei, and subcortical white matter as well as atrophy in the medial temporal 
lobe (Fig. 4b). Furthermore, single photon emission computed tomography and positron emission tomography 
(PET) images showed decreased signals in the striatum and temporal and parietal lobes, and [11C] Pittsburgh 
compound B (PiB) retention was observed on [11C] PiB PET (data not shown), which suggests that she also had 
Alzheimer’s disease. Unfortunately, the patient had not come to our hospital in the past. Then, we could not meas-
ure the level of PDGF-BB in the serum and produce iPS cells from the patient.
effects of variants on PDGFB mRNA splicing. To confirm the effect of PDGFB variants (Case 1, 
c.160 + 2T > A; Case 2, c.457−1G > T) on pre-mRNA splicing at the splice sites, the sequences between exons 
(Case 1, exons 2–3; Case 2, exons 4–6) were amplified via reverse transcription polymerase chain reaction 
(RT-PCR), followed by direct sequencing. The variant (c.160 + 2T > A) in Case 1 showed that the PCR products 
corresponded to the predicted lengths containing 172 bps of the unspliced intron between the exons (Fig. 5a,b). 
Figure 3. FIBGC (Case 2 in family 2). (a) Pedigree of family 2. The arrow indicates the index subject. Filled 
symbols represent patients with brain calcification. Participants’ ages are shown under the symbols in the 
pedigree. The symbols + and − indicate variant carriers and noncarriers, respectively. CT images of the 
proband (II-2) (b). Computed tomography (CT) image of her mother (I-2) with the variation (c). CT image 
of her younger brother (II-5) with the variation. The calcification of II-5 was mild (d). The calcification on CT 
images of the proband’s mother (I-2, C) was prominent compared to that of her children (II-2, B) and (II-5, D).
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For the variant (c.457−1G > T) in Case 2, the proband (Fig. 3a; II-2) and her third brother (Fig. 3; II-5) had 
lower-shifted PCR products corresponding with the transcript that lacks exon 5. By contrast, the cDNA of the 
controls did not have the shifted PCR products (Fig. 5c).
Levels of PDGF-BB protein in the sera of patients with PDGFB variants, those with SLC20A2 
variants, and healthy controls. PDGF-BB, a major dimeric glycoprotein, is composed of two subunits of 
PDGF-B. To determine the effect of the variants on PDGF-BB protein levels, we measured the PDGF-BB levels 
in the blood of patients with IBGC and healthy controls. Moreover, we measured those of patients with SLC20A2 
variants to clarify the presence of convergence into a common pathogenic mechanism. Enzyme-linked immu-
noassay (ELISA) analysis showed the PDGF-BB protein levels in the blood sera of three patients except for Case 
4 with PDGFB variants. Data of Case 4 were not available. The PDGF-BB protein levels of patients with PDGFB 
variants significantly decreased compared with those of the controls (34.0%) and those of patients with SLC20A2 
variant (40.0%) (p < 0.01 in Student’s t-test) (Table 2).
Endothelial cell differentiation from the iPSCs of patients with PDGFB variants. The establish-
ment of iPSCs had been successfully confirmed in in vitro differentiation study (Fig. 6a), genotyping analysis 
(Fig. 6b), and karyotype analysis (Fig. 6c). Differentiation into endothelial cells had been successfully performed 
from iPSCs according to the method with modified protocol22 (Fig. 7a). Their differentiation was identified via 
immunocytochemical study, and tubular formation was detected via morphological study (Fig. 7b). PDGF-BB 
protein levels in the culture media of the patients (Cases 1, 2, and 3) (22.9 ± 4.45 pg/μg protein) were significantly 
lower (58.6%) than those of healthy controls (39.1 ± 2.93 pg/μg protein) (p < 0.01 Student’s t-test). (Fig. 8).
Discussion
We have detected four novel variants of PDGFB in patients with IBGC. All variants are interpreted to be path-
ogenic according to ACMG/AMP variant classification guideline23,24 because they resulted in frameshifts or 
abnormal splicing leading to dynamic changes in protein translation. Several studies have reported pathogenic 
variants in PDGFB5,9,25–28. Most variants are thought to act as null variants. Some missense variants are predicted 
to act through loss of function mechanisms29. Species differences and region-specific susceptibility should be also 
examined in the future. In this study, in patients with PDGFB variants, PDGF-BB levels in the blood sera were 
down to less than half of those of controls and patients with SLC20A2 variants. The reduced PDGF-BB levels are 
assumed to be due to PDGF-B variant alleles which were expected as null variants.
In the survey, we identified four novel variants in PDGFB in 105 Japanese patients with IBGC. Among the 16 
families with FIBGC, the variant frequency of PDGFB was 12.5% [2 of 16 families]. The variant frequency in this 
study is similar to the frequencies (19%, [6 of 32 families]) in the first report5. Presently, in Japan, the main causa-
tive gene for FIBGC is SLC20A2 (31.3%, [5 of 16 families]) and the second causative gene is PDGFB (12.5%). The 
frequency of SLC20A2 variants in FIBGC (31.3%) was lower than that (50.0%, [5 of 10 families]) in our previous 
Figure 4. CT images. (a) Computed tomography (CT) images of Case 3 with PDGFB deletion variant 
(c.33_34delCT). (b) CT images of Case 4 with PDGFB insertion variant (c.342_343insG).
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study8 because the total number of familial patients has increased. Compared to the data reported by Ramos et 
al.10, Ramos et al., have screened 177 unrelated probands, and identified SLC20A2 variants at 16.9% (n = 30), 
followed by PDGFB at 3.4% (n = 6), PDGFRB at 1.7% (n = 3), and XPR1 at 3.4% (n = 6). In Japan, we identified 
16 probands (18.6%) carrying either pathogenic or likely pathogenic variants (12.8%, n = 11). SLC20A2 provided 
the contribution 8.1% (n = 7), followed by PDGFB at 4.7% (n = 4). We have examined SLC20A2 in all patients 
enrolled in the study. We have not identified any pathogenic variants on PDGFRB in Japan as far as we examined 
and have not investigated the genetic variants on XPR1 and MYORG. Two patients with sporadic IBGC who 
had PDGFB variants were identified in our analysis (Case 3, c.33_34delCT; Case 4, c.342_343insC). As de novo 
variants have been reported26,30, we should examine the DNA of their parents. A large deletion in the SLC20A231, 
and a partial deletion in the PDGFB27 were identified. In addition, XPR1 has been identified as a new causative 
gene for FIBGC (IBGC6)6. Recently biallelic variants in MYORG have been reported to cause autosomal recessive 
IBGC7. Genetic studies have been very useful to find key molecules in validating the pathogenesis of the disease. 
Further genetic studies including other autosomal recessive genes, large deletion or insertion, and copy number 
variant in IBGC will be needed.
PDGFB variants has been reported only in patients with IBGC. As its receptor, PDGFRβ is expressed in the 
brain microvascular pericytes in the central nervous system. PDGF-B is secreted from the neurons and vascular 
endothelial cells in the brain11,32,33. PDGFRB variants cause autosomal-dominant infantile myofibromatosis34–36. A 
point variation in PDGFRB also causes autosomal-dominant Penttinen syndrome36. Recently, the overexpression 
of PDGFRB due to the PDGFRB variants causes Kosaki overgrowth syndrome37–40.
Mice that are deficient in Pdgfrβ or Pdgfb lack brain pericytes, and impaired maturation of the blood brain 
barrier is fatal11, although heterozygous Pdgfb or Pdgfb knockout mice, as well as double Pdgfb+/−; Pdgfrb+/− 
mice, did not develop brain calcification29. Pdgfb-null mice rescued by transgenic re-expression of one human 
Pdgfb allele in only endothelium developed substantial brain calcification at age 1 year5. This mouse model is 
Figure 5. Patients with FIBGC who presented with PDGFRB splicing site variant. (a) (Case 1) Splicing patterns 
of PDGFB mRNA with a splicing site variant. mRNA from the patients’ blood was reverse transcribed, and 
cDNA sequences between exons 2 and 3 (including c.160 + 2T > A) were amplified via polymerase chain 
reaction (PCR). (b) (Case 1) Sequence of PDGFB mRNA with intron sequence that was removed. PCR 
products were purified and sequenced. Uppercase and lowercase letters indicate exon and intron sequences, 
respectively. The boxes represent differentially spliced exons. The boldface in red indicates the splice site 
variant (c.160 + 2T > A). (c) (Case 2) Splicing patterns of PDGFB mRNA with splice site variant. The mRNA 
from the patients’ blood was reverse transcribed, and the cDNA sequences between exons 4 and 6 (including 
c.457−1G > T) were amplified via PCR. The sequence of PDGFB mRNA with intron sequence that was 
removed. PCR products were purified and sequenced. The upper bands indicate the wild-type products, and the 
lower bands indicate the variant products that lack exon 5. The exon 5 was removed from PDGFB mRNA.
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supposed to correspond to the haplo-insufficiency of PDGF-B in patients with PDGFB variants. We observed 
decreased levels in the culture media of the endothelial cells differentiated from the iPS cells established from 
patients carrying the PDGFB variants, as similarly observed in the plasma of the patients. Although the causative 
role of low plasma PDGF-BB in development of brain calcification still remains unclear, the endothelial cells 
PDGF-BB (pg/mL) DNA Protein PolyPhen-2
PDGFB
Case 1 57/M 1900 c.160 + 2T > A — Not applicable
Case 2 16/F 1340 c.457 − 1G > T — Not applicable
Case 3 71/M 1730 c.33_34delCT p.Cys12Leufs*20 Not applicable
Case 4 53/F NE c.342_343insG p.Asn115Glnfs*52 Not applicable
Average (means ± SD) 1657 ± 287
SLC20A2*
Yamada et al. Case 1 64/F 4720 c.1909A > C p.Ser637Arg Probably damaging
Yamada et al. Case 3 69/F 3370 c.344C > T p.Thr115Met Probably damaging
Yamada et al. Case 5 24/M 4370 c.1399C > T p.Arg467Xaa Not applicable
Average (means ± SD) 4153 ± 700
Controls
Control 1 24/M 5030 — — —
Control 2 29/M 3890 — — —
Control 3 33/F 5690 — — —
Average (means ± SD) 4870 ± 910
Table 2. Serum levels of PDGF-BB. Abbreviations: NE = not examined. *Yamada M et al. Neurology 2014; 82: 
705–712.
Figure 6. Establishment of iPS cells obtained from patients. (a) Immunocytochemical study of iPS cells for the 
pluripotent marker NANOG, SSEA4, and differentiation markers for three germ layers, namely, βIII-Tubulin, 
αSMA, and Sox17. (b) Sequencing analysis of iPS cells. PDGF-B heterozygous base substitution resulted in 
variant c.33_34delCT, c.160 + 2T > A, and c.457 − 1G > T. (c) G-banded karyotype analysis of iPSCs. The scale 
bar shows 50 μm.
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differentiated from the iPS cells may serve as a cellular model for screening of compounds that are capable of 
restoring plasma PDGF-BB levels.
Interestingly, PDGF-BB administration stimulates the Pi transport in the aortic vascular smooth muscle cells 
of rats19. Recently, we have reported that Pi levels in patients with IBGC, particularly those with SLC20A2 vari-
ants, are higher than those of the controls20. This indicates that the basic mechanism of brain calcification is due 
to Pi dyshomeostasis in the CSF and interstitial space in the brain. We speculate that the increased Pi levels in 
the interstitial space and the perivascular space may contribute to the formation of calcification, more precisely 
mineralization through the formation of complex with Ca and heavy metals19. In contrast, the decreased Pi levels 
in the cell cytoplasm, especially in neurons, is supposed to cause clinical symptoms. On such assumption, 5-ALA 
has neuroprotective effects against low Pi in neuronal cells41. Although some issues should be elucidated, further 
studies using IBGC-specific iPSCs will give us more information on the pathophysiological mechanism of IBGC 
in the future. Collectively, appropriate stimulation by PDGF-BB may have beneficial effects on patients with 
IBGC. The endothelial cells developed from iPSCs of the patients showed a phenotype of the disease and they give 
us a useful tool for the study on IBGC.
Figure 7. Endothelial cell differentiation from iPSCs obtained from patients. (a) Endothelial cell differentiation 
from iPSCs. (b) Immunocytochemical study of endothelial marker CD31 and von Willebrand factor (vWF). 
Capillary tube formation on Matrigel for iPS-ECs.
Figure 8. Measurement of PDGF-BB released in the supernatant of iPS-derived endothelial cells using ELISA. 
iPSC-derived ECs were plated on 96-well plates and cultured for 116 h. Supernatant from iPSC-derived 
endothelial cells were measured using ELISA. Data were presented as means ± SD. Statistical significance was 
determined using Student’s t-test (**p < 0.01).
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Materials and Methods
Participants and samples. We collected clinical information on patients with IBGC in a nationwide study 
supported by a grant for research on intractable diseases from the Ministry of Health, Labour and Welfare of 
Japan. The diagnostic criteria were previously described7. Briefly, patients with causative biochemical abnor-
malities, such as high calcium levels, inorganic phosphate, and intact parathyroid hormone, were excluded. The 
genetic surveys were approved by the Ethics Committee of the Gifu University Graduate School of Medicine and 
the University of Tokyo. For genetic analysis, 105 patients from 87 hospitals provided written informed consent, 
and they were then enrolled in the project. Of these patients, 70 came from families with a single affected member, 
as shown in the available clinical data, and the other 35 patients came from 16 families with multiple members 
affected. We defined the former as patients with sporadic IBGC and the latter as patients with FIBGC. There 
were 51 male and 54 female patients. The patients’ mean age ± standard deviation (SD) was 46.7 ± 23.6 years 
at the time of registration. The 105 patients who were examined included 15 participants from 10 families with 
SLC20A2 variants, as revealed in a previous study. All experiments on human blood samples and iPS cells were 
approved by the Ethics Committees of Gifu University, Gifu Pharmaceutical University, the University of Tokyo 
and Kyoto University and performed in accordance with Ethical Guidelines for Medical and Health Research 
Involving Human Subjects in Japan, and Ethical Guidelines for Human Genome/Gene Analysis Research in 
Japan. After individual written informed consent was obtained, peripheral blood samples were collected. This 
study was registered to UMIN Clinical Trials Registry approved by International Committee of Medical Journal 
Editors (UMIN000030100).
Variant analysis. Genomic DNA was extracted from whole blood samples. In this study, variant analyses 
was performed by Sanger sequencing of all coding regions, and resequencing strategy was used on the basis 
of the VariantSEQr platform for the amplification of coding regions and their intron/exon junctions (Applied 
Biosystems). In the VariantSEQr resequencing system, each PCR primer was designed with priming sites tailed 
with either the M13 universal forward or reverse sequencing primer for PCR amplification and sequencing reac-
tion under similar PCR and sequencing conditions, as described in detail in the supplementary data (Table e-1). 
The functional effects of the identified variants were predicted using PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph/).
Transcript analysis. Total RNA was isolated from fresh blood using Tempus™ Blood RNA Tube and 
Tempus™ Spin RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA). For avoiding the amplification of 
genomic DNA, Absolute RNA Wash Solution (Thermo Fisher Scientific) was used during RNA isolation. cDNA 
was synthesized using SuperScript®III First-standard Synthesis Kit (Thermo Fisher Scientific). To determine the 
effect of splice site variants, RT-PCR was performed using primers spanning the exon–exon junctions (between 
exons 2 and 3; exons 4 and 6) and PrimeSTAR® HS DNA Polymerase (Takara Bio Inc.). PCR were separated using 
a 2% agarose gel. The corresponding bands were purified from the gel using Wizard® SV Gel and PCR Clean-Up 
System (Promega KK) and were confirmed via Sanger sequencing.
ELISA. The measurement of human PDGF-BB concentration in the blood was consigned to SRL, Inc. (Tokyo, 
Japan), using a Human PDGF-BB Quantikine ELISA kit (R&D Systems.), which does not recognize other human 
PDGFs, including the PDGF-AB heterodimer. iPSC-derived ECs were plated on 96-well plates and cultured for 
116 h. Supernatants from iPSC-derived ECs were measured using commercially available ELISA kits (Human 
PDGF-BB Quantikine ELISA kit [R&D Systems]) in accordance with the manufacturer’s instructions.
Establishment of iPSCs. Peripheral blood mononuclear cells from patients with IBGC who have PDGF-B 
variant (c.33_34 delCT, c.160 + 2T > A, and c.457−1G > T) were reprogrammed by inducing the episomal vec-
tors carrying OCT3/4, SOX2, KLF4, L-MYC, LIN28, EBNA1, and p53 carboxy-terminal dominant-negative 
fragment42. The obtained iPSCs were cultured on iMatrix-511 (Nippi, Tokyo, Japan)-coated plates with StemFit 
medium (Ajinomoto, Tokyo, Japan) supplemented with penicillin/streptomycin. Karyotyping was performed by 
LSI Medience Corporation (Tokyo, Japan). The genotyping of PDGF-B variant was performed by PCR amplifica-
tion of genomic DNA and direct sequencing (3500xL Genetic Analyzer, Thermo Fisher Scientific). CTK solution 
was used for harvesting iPSCs, and an embryoid body (EB) was formed. Cell masses were cultured in DMEM/F12 
(Thermo Fisher Scientific) comprising 20% knockout serum replacement (KSR, Thermo Fisher Scientific); 2 mM 
L-glutamine (Thermo Fisher Scientific); 0.1 M of nonessential amino acids (NEAA, Thermo Fisher Scientific); 
0.1 M of 2-mercaptoethanol (Thermo Fisher Scientific); and 0.5% penicillin/streptomycin. The medium was 
replaced every other day, and after 8 days, the EB was cultured for another 8 days in DMEM comprising 10% fetal 
bovine serum (FBS) on a gelatin-coated coverslip.
Immunocytochemistry. The cells were fixed with 4% paraformaldehyde and blocked with PBS containing 
5% FBS. DAPI (4′,6-diamidino-2-phenylindole) (Thermo Fisher Scientific) was used for labelling the nuclei. 
Fluorescence imaging was performed using IN CELL Analyzer 6000 (GE Healthcare). The following primary 
antibodies were used: NANOG (ReproCELL, Yokohama, Japan) (RCAB0003P, 1/500), SSEA-4 (Millipore) 
(MAB4304, 1/1,000), βIII-tubulin (Millipore) (CBL412, 1/500), SOX-17 (R&D Systems) (AF1924, 1/300), αSMA 
(DAKO, Glostrup Denmark) (M0851, 1/100), CD31 (Dako) (M023, 1/100), and vWF (Abcam, Cambridge, MA) 
(Ab6994, 1:400).
Endothelial cell differentiation. Regarding endothelial differentiation, on day 0, iPSC colonies were dis-
sociated into single cells with Accutase (Sigma). Cells were resuspended in basic medium containing StemPro34 
(Invitrogen), L-glutamine (Invitrogen), transferrin (Roche), monothioglycerol (Sigma), and ascorbic acid 
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(Sigma), and Y-27632 (naclai tesque), BMP-4 (Peprotech), and Matrigel (BD) were added to form EBs. On day 
1, the medium was supplemented with Activin A (R&D Systems) and BMP4. On day 4, EBs were seeded in 
Matrigel-coated dishes, and the medium was supplemented with VEGF (R&D Systems) for EC expansion. On day 
14, the EBs were harvested using Accutase (Sigma-Aldrich), and CD31 positive cells were positively sorted using 
magnetic-activated cell sorting using anti-CD31 (Miltenyi) (Fig. 7a).
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